Skip to main content

Table 1 Clinical data

From: Cost-effectiveness analysis of adjuvant chemotherapies in patients presenting with gastric cancer after D2 gastrectomy

Parameters

Values

Description and reference

Weibull survival model of RFS for surgery only

  

 1-97 weeks

Scale = 0.001554; Shape = 1.202; r2 = 0.9955

[2]

 Beyond 97 weeks

Scale = 0.02754; Shape = 0.5736; r2 = 0.9792

[2]

Weibull survival model of OS for surgery only

  

 1-141 weeks

Scale = 0.00005097; Shape = 1.755; r2 = 0.9977

[2]

 Beyond 141 weeks

Scale = 0.005259; Shape = 0.8171; r2 = 0.9935

[2]

HR of RFS (compared with surgery only)

  

 Adjuvant with S-1

0.653 (95% CI: 0.537-0.793)

[2]

 Adjuvant with XELOX strategy#

0.58 (95% CI: 0.47–0.72)

[27]

HR of OS (compared with surgery only)

 

[2]

 Adjuvant with S-1

0.669 (95% CI: 0.54-0.828)

 

 Adjuvant with XELOX strategy

0.66 (95% CI: 0.51–0.85)

[27]

  1. #We assumed that DFS in the CLASSIC trial was not better than RFS.